ES2038664T3 - Briostatinas. - Google Patents

Briostatinas.

Info

Publication number
ES2038664T3
ES2038664T3 ES198787306552T ES87306552T ES2038664T3 ES 2038664 T3 ES2038664 T3 ES 2038664T3 ES 198787306552 T ES198787306552 T ES 198787306552T ES 87306552 T ES87306552 T ES 87306552T ES 2038664 T3 ES2038664 T3 ES 2038664T3
Authority
ES
Spain
Prior art keywords
bryostatin
briostatinas
linneaeus
bryozoan
phylum
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES198787306552T
Other languages
English (en)
Inventor
George R. Pettit
Cherry L. Herald
Yoshiaki Kamano
John E. Leet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arizona State University
Original Assignee
Arizona State University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arizona State University filed Critical Arizona State University
Application granted granted Critical
Publication of ES2038664T3 publication Critical patent/ES2038664T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/22—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Vending Machines For Individual Products (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)

Abstract

NUEVOS AGENTES ANTIONEOPLASTICOS Y EXCEPCIONALMENTE POTENTES DENOMINADOS BRIOESTATINA 9, BRIOESTATINA 10, BRIOESTATINA 11, BRIOESTATINA 12 Y BRIOESTATINA 13 QUE SE HAN SEPARADO DEL ANIMAL MARINO BUGULA NERITINA (LINNEAEUS) (BRYOZOAN PHYLUM) Y LAS ESTRUCTURAS IDENTIFICADAS. CADA UNA DE ELLAS TIENE UNA ACTIVIDAD ANTINEOPLASTICA SIGNIFICATIVA.
ES198787306552T 1986-07-28 1987-07-24 Briostatinas. Expired - Lifetime ES2038664T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/889,946 US4833257A (en) 1986-07-28 1986-07-28 Compositions of matter and methods of using same

Publications (1)

Publication Number Publication Date
ES2038664T3 true ES2038664T3 (es) 1993-08-01

Family

ID=25396026

Family Applications (1)

Application Number Title Priority Date Filing Date
ES198787306552T Expired - Lifetime ES2038664T3 (es) 1986-07-28 1987-07-24 Briostatinas.

Country Status (8)

Country Link
US (1) US4833257A (es)
EP (1) EP0264173B1 (es)
JP (1) JP2626889B2 (es)
AT (1) ATE71627T1 (es)
CA (1) CA1305476C (es)
DE (1) DE3776063D1 (es)
ES (1) ES2038664T3 (es)
GR (1) GR3004061T3 (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5256646A (en) * 1990-07-27 1993-10-26 Bristol-Myers Squibb Company Antiviral antibiotic BU-4224V
US5072004A (en) * 1990-12-31 1991-12-10 Arizona Board Of Regents Acting On Behalf Of Arizona State University Synthetic conversion of bryostatin 2 into bryostatin 1
US5196447A (en) * 1991-08-08 1993-03-23 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting On Behalf Of Arizona State University Neristatin 1
US5436400A (en) * 1993-01-19 1995-07-25 Arizona Board Of Regents Isolation and structure of spongistatin 1
US5393897A (en) * 1993-07-02 1995-02-28 Arizona Board Of Regents Acting On Behalf Of Arizona State University Isolation and structure of spongistatins 5,7,8 and 9
US5684036A (en) * 1994-02-18 1997-11-04 Harbor Branch Oceanographic Institution, Inc. Cytotoxic macrolides and methods of use
US5478861A (en) * 1994-02-18 1995-12-26 Harbor Branch Oceanographic Institution, Inc. Cytotoxic macrolides and methods of use
WO1997034598A1 (en) * 1996-03-20 1997-09-25 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Method of treating cancer using c-26 modified bryostatin
US7256286B2 (en) * 1999-11-30 2007-08-14 The Board Of Trustees Of The Leland Stanford Junior University Bryostatin analogues, synthetic methods and uses
CA2393026A1 (en) * 1999-11-30 2001-06-07 Paul A. Wender Bryostatin analogues, synthetic methods and uses
JP2004536018A (ja) * 2000-07-31 2004-12-02 バル・イラン・ユニバーシティ 創傷治療のための方法および薬学的組成物
US20100129332A1 (en) * 2000-07-31 2010-05-27 Tamar Tennenbaum Methods and pharmaceutical compositions for healing wounds
US20060258562A1 (en) * 2000-07-31 2006-11-16 Healor Ltd. Methods and pharmaceutical compositions for healing wounds
US20040037828A1 (en) * 2002-07-09 2004-02-26 Bar-Ilan University Methods and pharmaceutical compositions for healing wounds
US20030148924A1 (en) * 2002-07-09 2003-08-07 Tamar Tennenbaum Methods and pharmaceutical compositions of healing wounds
US8026280B2 (en) 2001-03-27 2011-09-27 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors
US7312247B2 (en) * 2001-03-27 2007-12-25 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors
US6495719B2 (en) * 2001-03-27 2002-12-17 Circagen Pharmaceutical Histone deacetylase inhibitors
US7842727B2 (en) * 2001-03-27 2010-11-30 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors
WO2002087423A2 (en) * 2001-05-02 2002-11-07 Blanchette Rockefeller Neurosciences Institute Carbonic anhydrase activators for enhancing learning and memory
US20050065205A1 (en) * 2002-03-07 2005-03-24 Daniel Alkon Methods for Alzheimer's disease treatment and cognitive enhance
US20080004332A1 (en) * 2002-03-07 2008-01-03 Alkon Daniel L Methods for alzheimer's disease treatment and cognitive enhancement
US6825229B2 (en) 2002-03-07 2004-11-30 Blanchette Rockefeller Neurosciences Institute Methods for Alzheimer's Disease treatment and cognitive enhancement
US6900339B2 (en) 2002-04-30 2005-05-31 The University Of North Carolina At Chapel Hill Bryostatin composition and bryostatin acquisition methodologies
EP1511477A4 (en) * 2002-05-22 2008-04-09 Errant Gene Therapeutics Llc HISTONE DEACETYLASE INHIBITORS BASED ON ALPHA-KETO-EPOXYDE COMPOUNDS
CA2490494A1 (en) * 2002-07-02 2004-01-15 Blanchette Rockefeller Neurosciences Institute Pkc activation as a means for enhancing sapp.alpha. secretion and improving cognition using bryostatin type compounds
JP2006508986A (ja) * 2002-11-20 2006-03-16 エルラント ゲネ セラペウチクス エルエルシー ヒストンデアセチラーゼ阻害剤による肺細胞の治療方法
ES2375565T3 (es) * 2003-08-07 2012-03-02 Healor Ltd. Composiciones farmacéuticas y métodos para acelerar la cicatrización de heridas.
TW201207390A (en) * 2004-05-18 2012-02-16 Brni Neurosciences Inst Method for screening agent for antidepressant activity
CA2587013A1 (en) * 2004-11-08 2006-05-18 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors
US20070054890A1 (en) * 2005-07-29 2007-03-08 Alkon Daniel L Protein synthesis required for long-term memory is induced by PKC activation on days preceding associative learning
WO2007026356A2 (en) * 2005-08-29 2007-03-08 Healor Ltd. Methods and compositions for prevention and treatment of diabetic and aged skin
EP2762136A1 (en) 2006-07-28 2014-08-06 Blanchette Rockefeller Neurosciences, Institute Methods of stimulating cellular growth, synaptic remodeling and consolidation of long-term memory
ES2528033T3 (es) 2007-02-09 2015-02-03 Blanchette Rockefeller Neurosciences Institute Efectos terapéuticos de las briostatinas sobre la alteración de la memoria inducida por isquemia/accidente vascular cerebral y lesiones cerebrales
CN101848726A (zh) 2007-02-09 2010-09-29 布朗歇特洛克菲勒神经科学研究所 苔藓抑素、苔藓抑素类似物和其它相关物质对头部创伤引起的记忆缺陷和脑损伤的疗效
KR20100040912A (ko) * 2007-07-30 2010-04-21 힐로 리미티드 약제학적 조성물 및 관련 방법
NZ600583A (en) * 2009-02-24 2013-08-30 Healor Ltd Visfatin therapeutic agents for the treatment of acne and other conditions
EP2599494A1 (en) 2010-01-11 2013-06-05 Healor Ltd. PKC inhibitors for the treatment of inflammatory disease or disorder
EP2590642B1 (en) 2010-07-08 2018-03-14 Daniel L. Alkon Pkc activators and anticoagulant in regimen for treating stroke
JP6062362B2 (ja) 2010-08-19 2017-01-18 ブランシェット・ロックフェラー・ニューロサイエンスィズ・インスティテュート Ｐｋｃ活性化剤を使用した、異常な樹状突起棘に関連した認知障害の治療
WO2013071282A1 (en) 2011-11-13 2013-05-16 Blanchette Rockefeller Neurosciences Institute Pkc activators and combinations thereof
CN105008342B (zh) * 2012-11-27 2018-10-19 阿菲欧斯公司 苔藓素组合物、其制备方法和用途
US20180030095A1 (en) 2015-02-13 2018-02-01 George Robert Pettit Silstatin compounds
US20180217163A1 (en) 2015-05-11 2018-08-02 Daniel L. Alkon Treatment of neurodegenerative conditions using pkc activators after determining the presence of the apoe4 allele
WO2019094709A1 (en) 2017-11-09 2019-05-16 Pettit George R Betulastatin compounds

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4560774A (en) * 1982-11-17 1985-12-24 Arizona State University Macrocyclic lactones
JPS60174418A (ja) * 1984-02-18 1985-09-07 Ishikawajima Harima Heavy Ind Co Ltd 下水あるいはし尿汚泥等の流動層式焼却装置
US4611066A (en) * 1984-08-10 1986-09-09 Arizona State University Bryostatins 4 to 8

Also Published As

Publication number Publication date
CA1305476C (en) 1992-07-21
JPS63183585A (ja) 1988-07-28
DE3776063D1 (en) 1992-02-27
US4833257A (en) 1989-05-23
GR3004061T3 (es) 1993-03-31
EP0264173A3 (en) 1988-07-13
EP0264173B1 (en) 1992-01-15
ATE71627T1 (de) 1992-02-15
JP2626889B2 (ja) 1997-07-02
EP0264173A2 (en) 1988-04-20

Similar Documents

Publication Publication Date Title
DE3776063D1 (en) Bryostatine.
DE69020796D1 (de) Direkt-Elektroplattieren von Durchgangslöchern.
FI892429A7 (fi) Fuktogenomslaepplig kartongfoerpackning med haellnaebbsdel, som aer faest vid den innersta och yttersta ytan.
FI862256A0 (fi) Grundmjukgoerare som innehaoller katjoniskt ytaktivt medel och organisk syra.
FI891716L (fi) Hiv-proteasinhibitorer, som aer anvaendbara vid behandling av aids.
FI871750A7 (fi) Lääkeaineiden nenänsisäinen antaminen.
FI872027A7 (fi) Tetrahydronaftaliinijohdannaiset.
DE3764410D1 (de) Vielfachanordnung von lasern.
FI884867A0 (fi) Tandsticka och saett att framstaella den.
FI871171A0 (fi) Kombination bestaoende av en skidkaenga foer terraeng- och taevlingsskida och foer den avsedd bindning.
FI870589L (fi) Ny farmaceutisk sammansaettning och foerfarande foer framstaellning av den.
DK79487D0 (da) Synergistisk vandigt smoeremiddel og dets anvendelse
DE68910577D1 (de) Mittel gegen den AIDS-Virus.
FI872833A7 (fi) Anordning foer att aostadkomma lokalt verkande tryckkrafter pao en glasskiva innanfoer konturerna foer den bilglasskiva som utskaers.
FI871170L (fi) Kombination bestaoende av en skidkaenga foer terraeng- och taevlingsskida och foer den avsedd bindning.
EP0245456A4 (en) AIDS VIRUS GENE EXPRESSION.
DE3874594D1 (de) Gaenzlich waesserige formulierungen von organophosphorpestiziden.
FI864006A0 (fi) Foerfarande foer bestaemning av den totala karbonathalten speciellt i en biologisk vaetska.
ATE57526T1 (de) P-acylaminobenzamide.
FI874440L (fi) Trombolytisk sammansaettning och foerfarande foer framstaellning av den.
IT8720707A0 (it) Impiego del 2,4-monofurfuriliden-sorbitolo ad uso cosmetico.
NO875121D0 (no) Medikamenteringsform.
FI874976A7 (fi) Pyrazoliner, deras framstaellning och deras anvaendning som insekticid och akarizid verkan.
IT8545728A0 (it) Irroratore pulsante.
NO872632D0 (no) Forretningsformular.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 264173

Country of ref document: ES